Legal Information | Onco-Innovations

Subscribe Now

CBOE: ONCO

FSE: W1H

OTCQB: ONNVF

Legal

Effective Date: August 27, 2026

General Disclaimer

The information provided on this website (https://oncoinnovations.com) is for informational purposes only and should not be considered an offer, solicitation, or recommendation to buy or sell securities or other financial products of Onco-Innovations Limited ("Onco-Innovations" or the "Company"), a publicly traded company.

Onco-Innovations has taken all reasonable care in producing and publishing information on this website and will endeavor to update it regularly. However, the Company makes no representations or warranties as to the accuracy, completeness, or reliability of any information provided. Onco-Innovations assumes no liability for any errors, omissions, or inaccuracies in the content and disclaims responsibility for any losses or damages arising from reliance on the information contained herein.

By accessing and using this website, you agree to this disclaimer and its terms. Users are advised to conduct independent research or seek professional advice before making any investment decisions.

Forward-Looking Statements

This presentation contains “forward looking information” within the meaning of applicable Canadian securities legislation. Wherever possible, words such as “plans”, “expects”, or “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, have been used to identify forward looking information. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Onco-Innovations Limited (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Forward-looking statements contained in this investor presentation include statements with respect to: the Company’s DNA repair-targeted therapeutics with AI-driven precision oncology will redefine cancer treatment; the anticipated timing of the Company’s FDA submission and the First-in-Human (Phase I) trials; the anticipated tasks required to obtain IND approvals and the timing thereof; the Company’s plans regarding submissions to the FDA, EMA and Asia-Pacific regulatory agencies; the Company’s plans regarding the next level of AI patient identification and therapeutic intervention; the Company’s development of the SynographTM and its expected benefits to pharmaceutical companies and oncology treatment planning; the Company’s plans and anticipated timing regarding cross listing to a major US stock exchange; and the Company’s future PNKPi inventions.

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward looking statements in this investor presentation, the Company has made various material assumptions, including but not limited to: general business and economic conditions; failure to further develop, prove out or commercialize its technologies; successful integration and combined synergies from the acquisition of Inka Health AI; the Company’s ability to successfully execute its plans and intentions; the Company’s ability to maintain and renew patent rights as required; availability of financing on reasonable terms; market competition; market for and potential revenues to be derived from the Company’s products; costs, timing and future plans concerning operations of the Company will be consistent with current expectations; future interest rates; favorable operating conditions; the Company’s ability to attract and retain skilled personnel and directors; political and regulatory stability; competitive conditions; market (including labor, financial and capital market) conditions in Canada; timely receipt of governmental, regulatory and third-party approvals on favorable terms; and stability in the requirements placed on the Company under applicable laws. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and the Company cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including but not limited to: negative cash flows from operations; requirement of additional capital, which may not be available to the Company when required on attractive terms, if at all; the actual financial position and results of operations of the Company; significant ongoing costs and obligations relating to investments in infrastructure, growth, research and development, regulatory compliance and operations; the risk that preclinical results may not be predictive of clinical results; technology and artificial intelligence development, access, protection and use; protection, maintenance and enforcement of proprietary and intellectual property; litigation; conflicts of interests between the Company and its directors or management; adverse general economic conditions; dependence on key personnel; inflation-related risks; limits on insurance coverage and the occurrence of uninsurable risks; market price of the Company’s common shares; and the Company being subject to additional regulatory burden, including compliance with new and evolving artificial intelligence regulations.

Scientific and Technical Compliance

The scientific and technical information on this website has been prepared, reviewed, and approved by qualified professionals in the respective fields. The information is based on validated research, regulatory filings, and peer-reviewed studies.

Historical Data and Estimates

Certain information contained on this website may reference historical clinical data or research estimates. These data points are not current and should not be relied upon as definitive. A qualified professional has not completed sufficient work to classify historical research as current scientific findings, and Onco-Innovations is not treating historical data as definitive results.

Environmental and Social Responsibilities

Onco-Innovations is committed to conducting its research and operations in an environmentally and socially responsible manner while ensuring that its activities contribute positively to the well-being of communities. The Company adheres to regulatory standards and industry best practices to minimize its environmental impact.

Risk Factors

Investors are cautioned that the biotechnology and pharmaceutical industries involve numerous risks, including but not limited to:

Uncertainty in research outcomes and clinical trial results;
Fluctuations in market demand and regulatory approvals;
Intellectual property protection and potential legal disputes;
Operational challenges and unexpected scientific discoveries;
Capital market volatility and funding constraints;
Regulatory changes and compliance requirements;
Ethical considerations and public perception of biotechnology advancements.

These and other risk factors could materially impact Onco-Innovations operations and financial condition. Investors should carefully review all risk disclosures in the Company’s public filings before making any investment decisions.

Third-Party Links

This website may contain links to third-party sites. Onco-Innovations does not endorse or assume responsibility for external content or privacy practices. The inclusion of links does not imply any association with or endorsement by Onco-Innovations.

Stock Quotes

Stock price information provided on this website is sourced from third-party service providers and may be delayed by at least 20 minutes. Onco-Innovations does not guarantee the accuracy, completeness, or timeliness of stock price data. Any reliance on such information is at the user's own risk. Users are encouraged to seek independent financial advice before making investment decisions.

Personal Data & Privacy Policy

We collect and store personal information voluntarily provided by users, including names, email addresses, and company affiliations, for communication and regulatory compliance purposes. Onco-Innovations does not sell, rent, or share personal data with third parties except as required by law. Users may request access to or updates of their personal data by contacting investors@oncoinnovations.com.

This website also uses cookies and tracking technologies to enhance user experience. By browsing this site, users consent to data collection for analytics purposes. Users may disable cookies in their browser settings if they do not wish to be tracked.

No Solicitation

Material on this website is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction. Onco-Innovations does not assume any duty of disclosure beyond that required by applicable securities laws.